Semnur Pharmaceuticals, Inc. (SMNRW)

Semnur Pharmaceuticals is a clinical-stage pharmaceutical company developing novel pain therapies designed to treat moderate to severe chronic pain without opioids. The company’s lead candidate is SP-102 (branded SEMDEXA), a gel formulation administered epidurally — directly into the space around the spinal cord — rather than systemically. The company began trading publicly on the OTC markets in September 2025 following a business combination with a special purpose acquisition company. Semnur is majority-owned by Scilex Holding Company, a larger specialty pharmaceutical firm, which provides both strategic guidance and partial funding, but Semnur trades as a separate public entity with its own capital structure and warrants.

The pain market and the opioid alternative thesis

Chronic pain affects hundreds of millions of people worldwide. The standard treatment for moderate to severe pain has historically been opioid medications — drugs like morphine, oxycodone, and fentanyl that bind to opioid receptors in the nervous system. But opioids carry significant downsides: they are addictive, they cause respiratory depression (slowed breathing) in overdose, they lose efficacy over time (tolerance develops), and they cause constipation and cognitive effects that impair quality of life. The opioid crisis, particularly in North America, has driven a search for alternative pain-management strategies.

Semnur’s approach is to deliver a non-opioid compound directly to the site of pain perception — the spinal cord — in concentrations high enough to work without needing systemic doses. The rationale is that epidural delivery (similar to epidural anesthesia during childbirth) avoids many of the side effects of systemic pain medication because most of the drug acts locally rather than circulating through the entire body. The specific chemistry of SP-102 targets inflammatory and pain-signaling pathways that opioids do not address, aiming to provide pain relief through a different mechanism.

This is a genuine therapeutic innovation if it works. The opioid alternative market is enormous — tens of billions of dollars annually in global pain-management spending — and any credible non-opioid option that works at scale would likely capture a significant share.

Semnur’s capital history and ownership structure

Semnur was created in the early 2020s as a clinical-stage spinoff from Scilex, which itself is a specialty pharmaceutical company focused on pain management and neurology. Scilex retained approximately 87.5% ownership of Semnur, meaning Scilex controls the company and bears most of the financial risk, but allowed Semnur to become a public company so it could raise its own capital and create a distinct trading vehicle for investors who wanted exposure specifically to the SP-102 opportunity without exposure to Scilex’s other businesses.

The path to public equity was unconventional. Rather than a traditional initial public offering, Semnur merged with Denali Capital Acquisition Corp., a special purpose acquisition company (or SPAC) that had been formed specifically to acquire a biotech or healthcare target. Semnur was the target, and the merger closed in September 2025. This route is cheaper and faster than a traditional IPO but often results in lower share prices and more volatility because SPAC mergers are sometimes used by lower-quality businesses unable to pass traditional IPO underwriting.

Immediately upon going public, Semnur announced a novel funding arrangement: it would raise $100 million in new capital by selling shares to an institutional investor in exchange for $100 million in Bitcoin. This is extraordinarily unusual. Most pharmaceutical companies hold cash, Treasury securities, or money-market funds. Semnur chose to hold Bitcoin — a volatile digital asset with no intrinsic cash flow. This signals either an unconventional view of currency risk and value storage, or a pragmatic decision that Bitcoin is a cheaper source of capital at this moment in the market cycle than traditional equity or debt.

The clinical path and capital burn

SP-102 is in late-stage development, but not yet approved by the FDA. The company must conduct clinical trials to demonstrate safety and efficacy before filing a new drug application. The timeline for pain drugs typically runs 3–5 years from the start of human trials to FDA approval, assuming trials are successful.

Semnur’s burn rate (the rate at which it consumes cash to fund operations and trials) is not publicly disclosed in granular detail, but pharmaceutical companies at this stage typically burn $10–50 million annually depending on the trial scope and operational overhead. Semnur raised $100 million in Bitcoin, which at current Bitcoin prices represents a significant runway — perhaps 3–5 years if the company can avoid major trial setbacks or unexpected costs.

The risk is that clinical trials can fail or require redesign. If early trial data shows that SP-102 does not actually work better than placebo, the program is abandoned and the remaining cash is returned to shareholders or used to fund other programs. If trial data is positive but the FDA demands a larger or longer trial to confirm safety, costs escalate and the timeline extends.

Capital allocation in a majority-owned subsidiary

Semnur’s ownership structure creates an interesting capital dynamic. Scilex, as majority owner, has the right to consolidate Semnur’s financial results into its own consolidated statements if it chooses to. This means Scilex’s shareholders benefit from Semnur’s success, but they also bear the risk of Semnur’s failure. Scilex can also provide capital infusions if Semnur burns through its Bitcoin faster than expected, or strategic guidance if trial readouts require a pivot.

For Semnur’s public shareholders (the roughly 12.5% who are not Scilex), the investment is a call option on SP-102 approval and commercialization. If the drug is approved and sells well, those shares appreciate. If the drug fails, they are worthless. The fact that Scilex retains majority control is both good news and bad news: good because Scilex has the resources to fund trials even if they become expensive, bad because Semnur’s public shareholders have little control over capital allocation decisions.

Path to commercialization and profitability

If SP-102 is approved, Semnur will need to commercialize it — build a sales force, establish pricing and reimbursement with insurance companies and Medicare, and convince physicians to prescribe it. The pharmaceutical market requires a different skill set than clinical development, and most clinical-stage biotech companies partner with larger pharmaceutical firms for commercialization rather than building it in-house.

Scilex likely intends to commercialize SP-102 through its own infrastructure if approved, which would reduce Semnur’s capital needs but also transfer profit upside to Scilex (or to Scilex shareholders, which are not the same as Semnur shareholders). The exact commercialization strategy has not been publicly detailed.

The company remains years away from profitability. Even if SP-102 is approved in 2026 or 2027, the first years of sales would likely generate revenue below cost of goods sold plus sales overhead, meaning the company would still burn cash. Only if the drug becomes a significant commercial success — $200 million+ in annual revenue — would Semnur reach profitability without further financing.

Research pathways

Semnur’s public filings are limited because it trades on the OTC markets rather than NASDAQ or NYSE. The company should file a 10-K annually, but OTC companies have less rigorous disclosure requirements than Nasdaq-listed companies. The key events to monitor are clinical trial announcements (enrollment completion, interim efficacy or safety data, FDA interactions) and capital position updates. Scilex’s 10-K will also provide strategic context for Semnur, since Semnur is consolidated into Scilex’s results.

The most important single event is the announcement of SP-102 efficacy data from the pivotal trial. If the trial succeeds, Semnur will likely move toward FDA filing. If it fails, the company will likely be restructured or shut down. For shareholders, that binary outcome means Semnur shares are a bet on the science and the trial design — not a cash-generating business yet.